vimarsana.com
Home
Live Updates
Ianalumab, Ibrutinib Combination Promising in Chronic Lympho
Ianalumab, Ibrutinib Combination Promising in Chronic Lympho
Ianalumab, Ibrutinib Combination Promising in Chronic Lymphocytic Leukemia
Researchers determined ianalumab plus ibrutinib resulted in high response rates among patients with CLL.
Related Keywords
,
Eastern Cooperative Oncology Group ,
Novartis ,
Novartis Institutes For Biomedical Research ,
Janghee Woo ,
Novartis Institutes ,
Biomedical Research ,